| Genital Neoplasms, Female |
NCT01267461: Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells |
|
|
| Available | N/A | | RoW | Tissue sample from tumor | Meir Medical Center, Tel Aviv University | Endometrial Cancer, Colon Cancer | | | | |
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient |
|
|
| No Longer Available | N/A | | US | ficlatuzumab, AV-299, SCH 900105 | AVEO Pharmaceuticals, Inc. | Mullerian Mixed Tumor of Ovary | | | | |
NCT02950350: Clinical Trial of Laparoscopic Pelvic and Para-aortic Lymphadenectomy and Uterine Blood Vessel Blocking for Precision Diagnosis and Treatment in Advanced Cervical Cancer |
|
|
| Not yet recruiting | N/A | 50 | RoW | | Shanghai First Maternity and Infant Hospital | Cervical Cancer, Stage IIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage IIIB, Cervical Cancer, Stage IVA | 12/16 | 12/23 | | |
NCT03063710: Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan |
|
|
| No Longer Available | N/A | | Japan | olaparib | AstraZeneca | PSR Ovarian Cancer With a BRCA Mutation | | | | |
NCT02686463: Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy |
|
|
| Not yet recruiting | N/A | 150 | RoW | Laparoscopy, Laparotomy | Shengjing Hospital | Ovarian Cancer | 06/18 | 06/23 | | |
NCT01628757: Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer |
|
|
| Recruiting | N/A | 1400 | RoW | | Ding Ma, Zhejiang University, Shandong University, Sun Yat-sen University, Wuhan University, Hubei Women and Children's Hospital, Wuhan General Hospital of Guangzhou Military Command, Xiangfan Central Hospital, Wuhan Central Hospital, Hubei University for nationalities | Cervical Cancer | 12/18 | 12/23 | | |
NCT03006939: Fluid Balance During Surgery for Ovarian Cancer |
|
|
| Recruiting | N/A | 60 | Europe | Cytoreductive surgery | University Hospital, Bonn | Ovarian Neoplasm, Fluid Therapy | 12/19 | 12/22 | | |
| Active, not recruiting | N/A | 240 | RoW | TH, TH/BSO, BPLND | Ding Ma, Shandong University, Huazhong University of Science and Technology, Zhejiang University | Endometrial Neoplasms | 12/25 | 12/26 | | |
| Not yet recruiting | N/A | 50 | Europe | Blood sample | Assistance Publique Hopitaux De Marseille | Cervical Cancer | 09/24 | 09/24 | | |
| Enrolling by invitation | N/A | 10000 | Europe | Screening for cervical cancer | Tampere University, FinnMedi Oy, GlaxoSmithKline | Uterine Cervical Cancer | 12/24 | 12/24 | | |
NCT02869568: Institut Paoli Calmettes Ovarian Cancer Database |
|
|
| Recruiting | N/A | 6000 | Europe | Data collection | Institut Paoli-Calmettes | Ovarian Neoplasms | 01/30 | 12/30 | | |
NCT02869490: Institut Paoli Calmettes Cervical Cancer Database |
|
|
| Recruiting | N/A | 6000 | Europe | Data collection | Institut Paoli-Calmettes | Uterine Cervical Neoplasms | 01/30 | 12/30 | | |
| Recruiting | N/A | 3000 | RoW | | Kangbuk Samsung Hospital | Ovarian Neoplasms | 12/40 | 12/40 | | |
NCT01000259: Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer |
|
|
| Recruiting | N/A | 174 | US | Laboratory Biomarker Analysis | Gynecologic Oncology Group, National Cancer Institute (NCI) | Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer | 01/00 | | | |
NCT01164735: Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer |
|
|
| Completed | N/A | 169 | US | Laboratory Biomarker Analysis | Gynecologic Oncology Group, National Cancer Institute (NCI) | Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer | 01/18 | 01/18 | | |
NCT01198171: Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer |
|
|
| Completed | N/A | 243 | US | Laboratory Biomarker Analysis, Study of Socioeconomic and Demographic Variables | Gynecologic Oncology Group, National Cancer Institute (NCI) | Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer | 02/17 | 02/17 | | |
NCT01344837: Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer |
|
|
| Completed | N/A | 360 | US | Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Cell/Tissue, Immunohistochemistry, IHC, Immunohistochemistry, Medical Chart Review, Chart Review, Microarray Analysis, gene expression profile, Gene Expression Profiling, Microarray Technology, Microarray-Based Analysis, Study of Socioeconomic and Demographic Variables, Western Blotting, Blotting, Western, WESTERN BLOT | Gynecologic Oncology Group, National Cancer Institute (NCI) | Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer | 01/18 | 01/18 | | |
NCT01199250: Biomarkers in Samples From Patients With Endometrial Cancer |
|
|
| Withdrawn | N/A | 3600 | US | Laboratory Biomarker Analysis | Gynecologic Oncology Group, National Cancer Institute (NCI) | Lynch Syndrome, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer | 05/19 | 05/19 | | |
NCT01445275: Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 |
|
|
| Withdrawn | N/A | 2605 | US | Evaluation of Cancer Risk Factors, cancer risk factors evaluation, Medical Chart Review, Chart Review, Study of Socioeconomic and Demographic Variables | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma | 01/16 | | | |
